Vaginitis Therapeutics Global Market Report 2024

The vaginitis therapeutics market has grown rapidly in recent years. It will grow from $3.74 billion in 2023 to $4.12 billion in 2024 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historical period is associated with a high prevalence of vaginal infections, increased awareness of women's health, changes in lifestyles and hygiene practices, concerns about antibiotic resistance, and advancements in pharmaceutical research and development.

The vaginitis therapeutics market is expected to see rapid growth in the next few years. It will grow to $6.03 billion in 2028 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historical period is associated with a high prevalence of vaginal infections, increased awareness of women's health, changes in lifestyles and hygiene practices, concerns about antibiotic resistance, and advancements in pharmaceutical research and development.

The anticipated growth in the vaginitis therapeutics market is driven by the increasing prevalence of sexually transmitted diseases (STDs). Sexually transmitted diseases (STDs) are infections transmitted through sexual contact between infected and uninfected individuals, causing vaginitis, which leads to vaginal inflammation and pain. Vaginitis therapeutics play a crucial role in alleviating symptoms associated with STD-induced vaginitis among women, contributing to the widespread use of vaginitis drugs. For example, as of April 2023, the Center for Disease Control and Prevention reported a rise in STD cases in the USA, surpassing 2.5 million between 2020 and 2021. Syphilis cases saw a notable 32% increase from 133,954 in 2020 to 176,713 in 2021. Consequently, the escalating prevalence of STDs is expected to drive growth in the vaginitis therapeutics market.

Changing fertility trends are also poised to boost the vaginitis therapeutics market in the forthcoming years. Fertility, denoting the inherent capacity of an organism, person, or group to have children, is a critical aspect of human biology. Vaginitis therapeutics may enhance fertility by addressing underlying infections or illnesses that could impact reproductive health. Notably, as of June 2023, the Vital Statistics Rapid Release report from the Centers for Disease Control and Prevention highlighted a marginal decrease of less than 1% in the overall fertility rate from 2021, settling at 56.1 births per 1,000 women aged 15 to 44. Thus, changing fertility trends serve as a driving force behind the vaginitis therapeutics market.

Product innovation stands out as a prominent trend gaining traction in the vaginitis therapeutics market. Leading companies in this market are dedicated to developing inventive solutions to fortify their market presence. For example, Duchesnay Inc., a Canada-based pharmaceutical company specializing in women’s health, introduced Vablys, the pioneering prescription antiseptic and anti-infective treatment tailored for bacterial vaginosis in women under 55 years of age. With multiple modes of action and anti-infective properties against various pathogens, the treatment involves the insertion of one tablet into the vagina at bedtime for six consecutive days.

Major players in the vaginitis therapeutics market prioritize obtaining approvals for groundbreaking products, as exemplified by the U.S. Food and Drug Administration's (FDA) approval of SOLOSEC (secnidazole) for trichomoniasis treatment. SOLOSEC is an antibacterial medication designed to address bacterial vaginosis (BV) and trichomoniasis. Lupin Pharmaceuticals, Inc., a US-based pharmaceutical company, received FDA approval for the expanded use of SOLOSEC in adult trichomoniasis therapy. This authorization positions SOLOSEC as the sole single-dose oral prescription antibacterial medication approved for managing both BV and trichomoniasis, catering to the diverse needs of patients, including those 12 years of age and older.

In October 2021, BioNTech, a Germany-based biotechnology company, acquired PhagoMed, an Austria-based biotechnology company specializing in developing a new class of antibacterial drugs and treatments for recurrent bacterial vaginosis. This strategic acquisition aligns with BioNTech’s goal of enhancing its infectious disease portfolio capabilities, reinforcing its commitment to advancing innovative solutions in the vaginitis therapeutics market.

Major companies operating in the vaginitis therapeutics market report are Pfizer Inc., Merck & Co Inc., Novartis AG, Bayer AG, Lupin Pharmaceuticals Inc., Symbiomix Therapeutics Inc., Mission Pharmacal Company, Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals Inc., Lumavita AG, Abbott Laboratories Ltd., GlaxoSmithKline plc, Sanofi SA, Bristol-Myers-Squibb Co, Eli Lilly and Co, TherapeuticsMD Inc., Scynexis Inc., Sebela Pharmaceuticals Inc., Daré Bioscience Inc., Hologic Inc., Mylan N.V., Viamet Pharmaceuticals Inc., Matinas BioPharma Holdings Inc., Cidara Therapeutics Inc., Imprimis Pharmaceuticals Inc., Innovus Pharmaceuticals Inc., Evofem Biosciences Inc., Mycovia Pharmaceuticals, Perrigo Company plc, Mithra Pharmaceuticals, Ferring Pharmaceuticals, AstraZeneca plc, Biocon Limited, Pacira Pharmaceuticals Inc., The Medicines Company.

North America was the largest region in the global vaginitis therapeutics market in 2023. The regions covered in the vaginitis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vaginitis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary drug types for vaginitis therapeutics include nitroimidazole compounds, lincosamide antibiotics, triazoles, and imidazoles. Nitroimidazoles encompass a group of antimicrobial medications effective against parasites, mycobacteria, and anaerobic gram-positive and gram-negative bacteria. These drugs can be administered orally, topically, or vaginally, and they are indicated for conditions such as bacterial vaginosis, trichomoniasis, vulvovaginal candidiasis, and others. End users for these therapeutics include hospitals, ambulatory surgical centers, specialized gynecology centers, and clinics.

The vaginitis therapeutics market research report provides vaginitis therapeutics market statistics, including vaginitis therapeutics industry global market size, regional shares, competitors with a vaginitis therapeutics market share, detailed vaginitis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the vaginitis therapeutics industry. This vaginitis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vaginitis therapeutics market includes revenues earned by entities by nonhormonal therapy, and antioxidant therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.